E-LIB Suche - Ergebnisse für: Lockshin, B.

1

Long-term laboratory safety of dupilumab in patients aged 6..:

Crépy, M.N. ; Siegfried, E.C. ; Cork, M.J....
Revue Française d'Allergologie. 64 (2024) - p. 104044 , 2024

Link: https://doi.org/10.1016/..

2

Laboratory safety from a 16-week, phase 3 study of dupiluma..:

Paller, A.S. ; Wollenberg, A. ; Siegfried, E.C....
Revue Française d'Allergologie. 63 (2023) 3 - p. 103437 , 2023

Link: https://doi.org/10.1016/..

3

Dupilumab provides long-term efficacy for up to 4 years in ..:

Blauvelt, A. ; Thyssen, J.P. ; Lockshin, B....
Revue Française d'Allergologie. 62 (2022) 3 - p. 321 , 2022

Link: https://doi.org/10.1016/..

4

The National Psoriasis Foundation psoriasis treatment targe..:

Merola, J.F. ; Perez Chada, L.M. ; Siegel, M....
Journal of the European Academy of Dermatology and Venereology. 34 (2020) 9 - p. 2051-2058 , 2020

Link: https://doi.org/10.1111/..

5

A phase 2, open‐label study of single‐dose dupilumab in chi..:

Paller, A.S. ; Siegfried, E.C. ; Simpson, E.L....
Journal of the European Academy of Dermatology and Venereology. 35 (2020) 2 - p. 464-475 , 2020

Link: https://doi.org/10.1111/..

6

Le dupilumab améliore les signes et symptômes de dermatite ..:

Cork, M.J. ; Lockshin, B. ; Morren, M.-A....
Annales de Dermatologie et de Vénéréologie. 147 (2020) 12 - p. A362 , 2020

Link: https://doi.org/10.1016/..

7

Infra-red spectra and optical constants of polytetrafluoroe..:

Afanas'eva, N.I. ; Brame Jr, E.G. ; Lockshin, B.V..
Polymer. 27 (1986) 4 - p. 503-509 , 1986

Link: https://doi.org/10.1016/..

8

Fear of Routine Physical Exams in Children With Autism Spec..:

Gillis, Jennifer M. ; Hammond Natof, Tammy ; Lockshin, Stephanie B..
Focus on Autism and Other Developmental Disabilities. 24 (2009) 3 - p. 156-168 , 2009

Link: https://doi.org/10.1177/..

9

Laboratory safety from a randomized 16-week phase III study..:

Paller, A.S ; Siegfried, E.C ; Cork, M.J...
https://eprints.whiterose.ac.uk/195120/1/s40272-022-00553-8.pdf. , 2023

Link: https://eprints.whiteros..

10

A phase 2, open‐label study of single‐dose dupilumab in chi..:

Paller, A.S ; Siegfried, E.C ; Simpson, E.L...
https://eprints.whiterose.ac.uk/177102/6/jdv.16928.pdf. , 2021

Link: https://eprints.whiteros..

11

A phase 2, open‐label study of single‐dose dupilumab in chi..:

Paller, A.S ; Siegfried, E.C ; Simpson, E.L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894166/. , 2020

Link: http://www.ncbi.nlm.nih...

12

New trends in cell death: overview of the International Soc..:

Cronjé, Marianne J. ; Gadiyar, Varsha ; Chipuk, Jerry Edward...
Cell Communication and Signaling. 22 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

13

List Of Contributors:

, In: Clinical Immunology,

Abraham, Roshini Sarah ; Afzali, Behdad ; Águeda, Ana... - p. xiii-xxv , 2023

Link: https://doi.org/10.1016/..

14

Modification of immunomodulatory medications by rheumatolog..:

Barbhaiya, Medha ; Frey, Marianna B. ; Levine, Jonah...
Clinical Rheumatology. 41 (2022) 8 - p. 2597-2599 , 2022

Link: https://doi.org/10.1007/..

15

Efficacy, safety, usability, and acceptability of risankizu..:

Blauvelt, Andrew ; Gordon, Kenneth B. ; Lee, Patricia...
Journal of Dermatological Treatment. 33 (2021) 4 - p. 2085-2093 , 2021

Link: https://doi.org/10.1080/..